Double blind clinical trial of lemborexant for AD prevention: Protocol for a randomized controlled clinical trial

Abstract

Background: Poor sleep is a modifiable factor associated with the development and progression of Alzheimer’s Disease (AD). Pharmacological treatments and Cognitive Behavioural Therapy for Insomnia (CBT‐I) which promote sleep have the potential to improve AD risk profile.